
Pharmaceutical giant AstraZeneca PLC (AZN) is a specialist in cancer treatments. In fiscal year 2023, it derived $18.4 billion and 40% of its sales from oncology products.
So it’s not a surprise that the company decided to move into the latest, next-generation treatments for cancer - radiopharmaceutical drugs. On March 19, AstraZeneca announced it will buy Canadian drug developer Fusion Pharmaceuticals (FUSN) for $2.4 billion. The deal involves a $2 billion upfront cash transaction, with a total transaction value of $2.4 billion based on contingent, further payments.